Idenix Pharmaceuticals Inc

Idenix Pharmaceuticals — Corporate Update (January 2012)

13 slides from Idenix Pharmaceuticals's corporate update, Jan 9, 2012

  1. Slide 1: Interim IDX184 Phase IIb Data and Development Pipeline Update Conference Call

    1 Interim IDX184 Phase IIb Data and Development Pipeline Update Conference Call January 9, 2012

  2. Slide 2: Safe Harbor Statement

    2 Building a Leading Antiviral Franchise Safe Harbor Statement This presentation includes forward-looking statements about Idenix and its business, including without limitation, statements regarding drug discovery, research and clinical development, regulatory approval processes and market opportuni

  3. Slide 3: IDX184 Phase IIb Interim Results

    3 Building a Leading Antiviral Franchise IDX184 Phase IIb Interim Results

  4. Slide 4: Attractive Target Product Profile

    Attractive Target Product Profile Pan-genotypic High barrier to resistance Once-daily dosing (QD) Low dose amenable to both co-administration and to fixed dose co-formulation Low potential of drug-drug interaction with CYP 450; no known transporter interactions Demonstrated safety and antiviral acti

  5. Slide 5: 12-Week Combination Study Overview

    5 Building a Leading Antiviral Franchise Study Design 12-week, randomized, double-blind, parallel groups 100 treatment-naive, genotype 1, HCV-infected patients 50 patients receiving 50 mg IDX184 with PegIFN/RBV 50 patients receiving 100 mg IDX184 with PegIFN/RBV Response-guided PegIFN/RBV extension

  6. Slide 6: 12-Week Combination Study Interim Analysis at 28 Days of Treatment

    Safety: Safety observed to date consistent with known safety profile of PegIFN/RBV No serious adverse events IDX184 Phase IIb 12-Week Combination Study Interim Analysis at 28 Days of Treatment 6 Building a Leading Antiviral Franchise n Median Time to LLOQ 50 mg IDX184 + Peg/RBV 16 22 days 100 mg IDX

  7. Slide 7: Potent Activity Compared to PegIFN/RBV Historical Control

    7 Building a Leading Antiviral Franchise IDX184 Phase IIb 12-Week Combination Study Potent Activity Compared to PegIFN/RBV Historical Control HCV RNA Assay: COBAS Taqman, v. 2.0 with lower limit of quantitation (LLOQ) of 25 IU/mL Excluded from analysis: 1 subject lost to follow up after Day 1 with n

  8. Slide 8: Status and Next Steps

    8 Building a Leading Antiviral Franchise IDX184 Phase IIb Status and Next Steps DSMB concluded that there was no evidence of hepatoxicity and recommended that the study continue after review of the interim data of first 31 patients Interim data of 31 patients and DSMB's recommendations were submitte

  9. Slide 9: HCV Development Pipeline Update

    9 Building a Leading Antiviral Franchise HCV Development Pipeline Update

  10. Slide 10: NS5A Inhibitor IDX719 Strong Activity Profile

    10 Building a Leading Antiviral Franchise NS5A Inhibitor IDX719 Strong Activity Profile Phase I clinical trial initiated in January 2012 in healthy volunteers with proof-of-concept to follow in 2Q 2012 Potent broad genotypic activity against genotypes 1a, 1b, 2a, 3a, 4a and 5a with high selectivity

  11. Slide 11: NS5A Inhibitor IDX719 Promising Profile for Combination Therapy

    NS5A Inhibitor IDX719 Promising Profile for Combination Therapy Clean preclinical safety profile to date Potential for low mg doses and QD dosing in humans No in vitro interaction with 7 human CYP 450 enzymes at 10 µM (well above physiologic concentrations) No significant interaction with human tran

  12. Slide 12: Novel Nucleotide Prodrug Program

    Novel Nucleotide Prodrug Program Intensive program in place Robust synthetic and screening efforts ongoing, focus on single diastereomers Diverse spectrum of nucleotides Purines and pyrimidines Known prodrugs and novel prodrugs 2' Me sugars and some novel sugars Identify promising compounds in vitro

  13. Slide 13: 2012: An Eventful Year Expected to Create Value

    13 Building a Leading Antiviral Franchise 2012: An Eventful Year Expected to Create Value IDX184: Nucleotide HCV Polymerase Inhibitor Potential removal of the partial clinical hold Combine with one or more DAAs for combination regimen and initiate broad Phase IIb trials Establish non-exclusive/exclu

Idenix Pharmaceuticals — Corporate Update (January 2012) on 6ix